Skip to content
Natera

Senior Director, Development - ECD and MCED Products

San Carlos, CA; US - CA - SC Industrial RdUnited States
Director+ · Bio Development
POSTED 14 OCTVERIFIED 1H AGO
Apply Ask
Role
32 days opentrue age
Past the 31d median close
Posted 14 Oct · n=78
Payats field
$268k–335kposted
▲ +44% vs market median $210k
$94k$335k
Market p25–p75
$165k–$255k
Natera p25–p75
$178k–$262kn=24
H-1B median · Other
$94k
United States · n=6128 · 365d to 15 Nov
CompanyNatera →
212open roles
Opened · 30d
+58
Closed · 30d
−64
Signal
● Steady−6 net
15d of snapshots · 30d window
Market
25,434open · Director+ Other
Opened · 7d
+2,55710% of open
All other
622,317open
All tracked boards · live 16 Nov · n=25,434
Visa
48H-1B LCAs · FY26
PERM · FY26
7
Median wage
$132k
LCAs FY26 · n=48 · to 2026-06-29
Go

POSITION SUMMARY

Join Natera as the Senior Director of Development for our Early Cancer Detection (ECD) and Multi-Cancer Early Detection (MCED) portfolio. You will take ownership of product development strategy and execution, guiding Next-Generation Sequencing (NGS) and cell-free DNA-based (cfDNA) In Vitro Diagnostic (IVD) products from feasibility through FDA Premarket Approval (PMA) and post-market support. Every test represents a real person, and you will build an organization of scientific contributors and managers to deliver robust clinical tools. You will establish priorities, allocate resources, and represent development with the FDA and executive leadership, ensuring that scientific rigor and data drive all regulatory and portfolio decisions.

PRIMARY RESPONSIBILITIES

  • Define and own the multi-year assay development strategy and technical lifecycle for the ECD and MCED portfolio, in alignment with corporate and R&D strategy
  • Take accountability for the phase-gated execution of all ECD and MCED programs, overseeing the development, design verification, and validation of NGS-based cancer detection IVD devices using cfDNA, methylation and other analyte classes.
  • Set team priorities, allocate people, budget, and laboratory resources, and make or recommend go/no-go decisions to executive leadership
  • Establish the analytical verification and validation strategy for the portfolio to ensure robust assays transfer seamlessly to commercial manufacturing
  • Partner with clinical, medical, and biostatistics leaders to support approvable pivotal and prospective study design, statistical analysis plans, and performance claims for screening-population use in both the ECD and MCED intended-use claims
  • Define regulatory pathways and evidence requirements for PMA submissions for ECD and MCED in an evolving regulatory landscape. Be facile in representing the Development approach and activities in senior-level engagement with the FDA (e.g., pre-submission meetings and advisory panels, as applicable) and accountable for the analytical performance data packages supporting each submission
  • Build, retain, and mentor a leadership team of directors, managers, and scientists, optimizing the organization’s budget and external vendor partnerships
  • Think team by partnering directly across research, bioinformatics, biostatistics, software, clinical, regulatory, and commercial functions to deliver design-controlled IVD products in a highly cross-functional environment
  • Communicate portfolio status, risks, and tradeoffs to executive leadership and drive alignment on enterprise priorities
  • Ensure the organization operates within Natera’s QMS and all applicable guidance (ISO 13485:2016, FDA QMSR (21 CFR Part 820), ISO 14971, IEC 62304, etc), and partner with Quality to maintain audit readiness and strengthen design control practices

REQUIRED QUALIFICATIONS

  • Advanced degree (PhD, MD, or equivalent) in Molecular Biology, Biomedical Engineering, Life Sciences, or a related field
  • 7+ years of experience in IVD or diagnostic device development under design controls
  • 7+ years of experience directing scientific or technical organizations, with 5+ years managing senior managers or directors

KNOWLEDGE, SKILLS, AND ABILITIES

  • Demonstrated experience managing multiple concurrent development programs, with full accountability for budget, resource allocation, and prioritization
  • Deep technical expertise with complex NGS-based diagnostic assays, including assay design, analytical validation, and transfer to a commercial laboratory
  • Demonstrated leadership of the technical and performance evidence for at least one FDA premarket submission (PMA, De Novo, or equivalent high-complexity IVD approval) for an NGS-based device, including senior-level FDA interactions
  • Experience in liquid biopsy or molecular diagnostics for clinical oncology, specifically cfDNA-based detection of low-abundance signals at high specificity
  • Push for clarity and outcome-driven action at the executive level, taking ownership of technical and programmatic challenges without relying on a finished playbook
Source · NateraFirst seen 2 NovOriginal ↗